JP2023518035A5 - - Google Patents
Info
- Publication number
- JP2023518035A5 JP2023518035A5 JP2022555625A JP2022555625A JP2023518035A5 JP 2023518035 A5 JP2023518035 A5 JP 2023518035A5 JP 2022555625 A JP2022555625 A JP 2022555625A JP 2022555625 A JP2022555625 A JP 2022555625A JP 2023518035 A5 JP2023518035 A5 JP 2023518035A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- compound according
- inhibitor
- halo
- amino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2020/079464 | 2020-03-16 | ||
| PCT/CN2020/079464 WO2021184154A1 (en) | 2020-03-16 | 2020-03-16 | Compounds for treating or inhibiting recurrence of acute myeloid leukemia |
| PCT/US2021/022322 WO2021188417A1 (en) | 2020-03-16 | 2021-03-15 | Compounds for treating or inhibiting recurrence of acute myeloid leukemia |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023518035A JP2023518035A (ja) | 2023-04-27 |
| JP2023518035A5 true JP2023518035A5 (cg-RX-API-DMAC7.html) | 2024-03-27 |
| JP7744358B2 JP7744358B2 (ja) | 2025-09-25 |
Family
ID=77767943
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022555625A Active JP7744358B2 (ja) | 2020-03-16 | 2021-03-15 | 急性骨髄性白血病の再発を処置または阻害するための化合物 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US11963960B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4121430A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7744358B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102990081B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN115298180B (cg-RX-API-DMAC7.html) |
| AR (1) | AR121570A1 (cg-RX-API-DMAC7.html) |
| AU (2) | AU2020436612A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022018345A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3168988A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL296296A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022011407A (cg-RX-API-DMAC7.html) |
| PE (1) | PE20230461A1 (cg-RX-API-DMAC7.html) |
| PH (1) | PH12022552169A1 (cg-RX-API-DMAC7.html) |
| TW (1) | TWI899184B (cg-RX-API-DMAC7.html) |
| WO (2) | WO2021184154A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2020436612A1 (en) | 2020-03-16 | 2022-09-01 | Flash Therapeutics, Llc | Compounds for treating or inhibiting recurrence of acute myeloid leukemia |
| CA3182276A1 (en) | 2020-05-08 | 2021-12-02 | Halia Therapeutics, Inc. | Inhibitors of nek7 kinase |
| AU2021289345A1 (en) * | 2020-06-08 | 2023-01-19 | Halia Therapeutics, Inc. | Inhibitors of NEK7 kinase |
| CN114075190A (zh) | 2020-08-20 | 2022-02-22 | 北京诺诚健华医药科技有限公司 | 杂环类btk抑制剂 |
| CN113861179A (zh) * | 2021-10-22 | 2021-12-31 | 上海应用技术大学 | 一种新型flt3激酶抑制剂及其合成与应用 |
| WO2025124429A1 (zh) * | 2023-12-11 | 2025-06-19 | 北京康辰药业股份有限公司 | 芳香胺化合物及其药物组合物、应用 |
| WO2025151010A1 (ko) * | 2024-01-11 | 2025-07-17 | 주식회사 펠레메드 | 신규한 피롤로트리아진 유도체 및 이의 용도 |
| KR20250157634A (ko) | 2024-04-29 | 2025-11-05 | 대한민국(질병관리청 국립보건연구원장) | Bax 활성제를 유효성분으로 포함하는 항-hiv-1 조성물 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR9808281A (pt) | 1997-03-19 | 2000-05-16 | Basf Ag | Compostos, composições farmacêuticas, processo para tratar doenças proliferativas e/ou distúrbios do sistema imune e para preparar um composto, e, uso de um composto |
| NZ510588A (en) | 1998-09-18 | 2003-08-29 | Abbott Gmbh & Co | Pyrrolopyrimidines as protein kinase inhibitors |
| US6713474B2 (en) * | 1998-09-18 | 2004-03-30 | Abbott Gmbh & Co. Kg | Pyrrolopyrimidines as therapeutic agents |
| US6921763B2 (en) | 1999-09-17 | 2005-07-26 | Abbott Laboratories | Pyrazolopyrimidines as therapeutic agents |
| KR20020088406A (ko) * | 1999-09-17 | 2002-11-27 | 애보트 게엠베하 운트 콤파니 카게 | 치료제로서의 피라졸로피리미딘 |
| MXPA03008560A (es) * | 2001-03-22 | 2004-06-30 | Abbot Gmbh & Co Kg | Pirazolopirimidinas como agentes terapeuticos. |
| WO2005074603A2 (en) * | 2004-02-03 | 2005-08-18 | Abbott Laboratories | Aminobenzoxazoles as therapeutic agents |
| BRPI0619146A2 (pt) | 2005-12-02 | 2011-09-13 | Bayer Pharmaceuticals Corp | derivados de 4-amino-pirroltriazina substituìda úteis no tratamento de disordens e doenças hiperproliferativas associadas com angiogênesis |
| US7772231B2 (en) | 2005-12-29 | 2010-08-10 | Abbott Laboratories | Substituted pyrazolo[3,4-d]pyrimidines as protein kinase inhibitors |
| EP2139487B1 (en) | 2007-03-28 | 2015-11-11 | Pharmacyclics LLC | Inhibitors of bruton's tyrosine kinase |
| ES2396613T3 (es) | 2008-05-19 | 2013-02-22 | OSI Pharmaceuticals, LLC | Imidazopirazinas e imidazotriazinas sustituidas |
| JP6327713B2 (ja) | 2012-07-27 | 2018-05-23 | 国立研究開発法人理化学研究所 | 急性骨髄性白血病の治療又は再発抑制剤 |
| USRE48175E1 (en) * | 2012-10-19 | 2020-08-25 | Dana-Farber Cancer Institute, Inc. | Hydrophobically tagged small molecules as inducers of protein degradation |
| CN105017256A (zh) | 2014-04-29 | 2015-11-04 | 浙江导明医药科技有限公司 | 多氟化合物作为布鲁顿酪氨酸激酶抑制剂 |
| WO2016019237A2 (en) | 2014-07-31 | 2016-02-04 | Pharmacyclics Llc | Inhibitors of bruton's tyrosine kinase |
| US10266535B2 (en) | 2015-01-21 | 2019-04-23 | Hefei Institutes Of Physical Science, Chinese Academy Of Sciences | Inhibitor of FLT3 kinase and use thereof |
| GB201508747D0 (en) | 2015-05-21 | 2015-07-01 | Univ Edinburgh | Compounds |
| US20190255056A1 (en) | 2016-09-15 | 2019-08-22 | Riken | A hck inhibitor and a bcl-2 inhibitor for treating acute myeloid leukemia |
| CN118027041A (zh) * | 2019-05-31 | 2024-05-14 | 西藏海思科制药有限公司 | 一种btk抑制剂环衍生物及其制备方法和药学上的应用 |
| AU2020301399B2 (en) | 2019-06-24 | 2025-12-18 | Dana-Farber Cancer Institute, Inc. | HCK degraders and uses thereof |
| CN114746095B (zh) | 2019-10-08 | 2025-01-24 | 达纳-法伯癌症研究所有限公司 | Hck作为myd88突变疾病的治疗靶点 |
| MX2022008148A (es) * | 2020-01-02 | 2022-07-21 | Dizal Jiangsu Pharmaceutical Co Ltd | Inhibidores de btk. |
| AU2020436612A1 (en) | 2020-03-16 | 2022-09-01 | Flash Therapeutics, Llc | Compounds for treating or inhibiting recurrence of acute myeloid leukemia |
-
2020
- 2020-03-16 AU AU2020436612A patent/AU2020436612A1/en active Pending
- 2020-03-16 WO PCT/CN2020/079464 patent/WO2021184154A1/en not_active Ceased
-
2021
- 2021-03-12 AR ARP210100645A patent/AR121570A1/es not_active Application Discontinuation
- 2021-03-15 MX MX2022011407A patent/MX2022011407A/es unknown
- 2021-03-15 CA CA3168988A patent/CA3168988A1/en active Pending
- 2021-03-15 US US17/201,827 patent/US11963960B2/en active Active
- 2021-03-15 JP JP2022555625A patent/JP7744358B2/ja active Active
- 2021-03-15 IL IL296296A patent/IL296296A/en unknown
- 2021-03-15 EP EP21772015.0A patent/EP4121430A4/en active Pending
- 2021-03-15 AU AU2021239828A patent/AU2021239828B2/en active Active
- 2021-03-15 PH PH1/2022/552169A patent/PH12022552169A1/en unknown
- 2021-03-15 KR KR1020227035324A patent/KR102990081B1/ko active Active
- 2021-03-15 CN CN202180016180.0A patent/CN115298180B/zh active Active
- 2021-03-15 BR BR112022018345A patent/BR112022018345A2/pt not_active IP Right Cessation
- 2021-03-15 PE PE2022001990A patent/PE20230461A1/es unknown
- 2021-03-15 WO PCT/US2021/022322 patent/WO2021188417A1/en not_active Ceased
- 2021-03-16 TW TW110109254A patent/TWI899184B/zh active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6505013B2 (ja) | スルファモイル−アリールアミド及びb型肝炎の治療のための薬剤としてのその使用 | |
| JP2026031940A (ja) | Shp2の活性を阻害するための化合物の製造方法 | |
| CN101663282B (zh) | 包含β-氨基的DPP-Ⅳ抑制剂及其制备方法以及用于预防和治疗糖尿病或肥胖症的含有所述抑制剂的药物组合物 | |
| EP3917916A1 (en) | Bi-functional compounds and methods for targeted ubiquitination of androgen receptor | |
| JP2021534124A5 (cg-RX-API-DMAC7.html) | ||
| JP4220897B2 (ja) | ピペラジン化合物 | |
| JP2007505931A5 (cg-RX-API-DMAC7.html) | ||
| JP2009537550A5 (cg-RX-API-DMAC7.html) | ||
| JP2023533447A5 (cg-RX-API-DMAC7.html) | ||
| CN107660202B (zh) | 水溶性前药 | |
| ES3055488T3 (en) | Tegavivint for use in the treatment of pulmonary fibrosis | |
| JP2013537195A5 (ja) | 疾患を治療するための医薬品及び同医薬品を含むキット | |
| JP2022522486A5 (cg-RX-API-DMAC7.html) | ||
| JP2010521483A5 (cg-RX-API-DMAC7.html) | ||
| JP2020505457A (ja) | 2−アリールスルホンアミド−N−アリールアセトアミド誘導体化Stat3 | |
| CN102482256B (zh) | N-取代的环状氨基衍生物 | |
| JP2015521617A5 (cg-RX-API-DMAC7.html) | ||
| JPWO2008099874A1 (ja) | ピラジン誘導体を含有する医薬組成物およびピラジン誘導体を組み合わせて使用する方法 | |
| JP2022537140A5 (cg-RX-API-DMAC7.html) | ||
| IL290882B1 (en) | Pyrazole compounds, formulations thereof, and a method for using the compounds and/or formulations | |
| AU2020221247B2 (en) | Formulations comprising heterocyclic protein kinase inhibitors | |
| EP3860991A1 (en) | Monomer and multimeric anti-hbv agents | |
| IL293703A (en) | Lysine-specific histone demethylase inhibitors for the treatment of myeloproliferative neoplasms | |
| JP2012506908A5 (cg-RX-API-DMAC7.html) | ||
| JP2006512321A5 (cg-RX-API-DMAC7.html) |